Akshat Ayush

Indus Towers shares gain 3% after Nomura reiterates 'Buy'; sees 30% upside

Nomura has maintained a 'Buy' rating on Indus Towers. The brokerage has kept its target price unchanged at ₹505, implying an upside of 30 per cent from its previous close of ₹388.55.

Piramal Pharma shares rise 4% on successful closure of US FDA inspection

Piramal Pharma said that the US FDA has issued an Establishment Inspection Report (EIR) for its Sellersville facility, and the inspection has now been successfully closed.

Q1FY27 aviation preview: Analysts advise watching crude and rupee impact

Q1FY27 aviation preview: Key monitorables, Elara Capital said, are the extent of impact on international operations and rise in fuel/non-fuel costs from lower aircraft utilisation & rupee weakening

Nomura retains 'buy' on Uno Minda amid expansion plans, sees 33% upside

The company had been manufacturing seat recliners since 2022, but is now expanding to manufacture complete seating systems.

Eternal stock up 2%; Motilal Oswal retains buy for 31% upside

Motilal Oswal Financial Services has reiterated its 'Buy' rating on Eternal stock for a target price of ₹380, implying an upside of 31 per cent from its current price.